MAP2K7 and melanoma: Fortunately, angiogenesis inhibitors might be suitable for BRAF-mutant melanoma patients with acquired resistance to BRAF/MEK inhibitors (Amann et al., 2017; Martin et al., 2018; Atzori et al., 2020).